Annual SG&A:
$1.46B+$327.70M(+28.83%)Summary
- As of today, VRTX annual SG&A is $1.46 billion, with the most recent change of +$327.70 million (+28.83%) on December 31, 2024.
- During the last 3 years, VRTX annual SG&A has risen by +$624.20 million (+74.30%).
- VRTX annual SG&A is now at all-time high.
Performance
VRTX SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly SG&A:
$424.60M+$28.20M(+7.11%)Summary
- As of today, VRTX quarterly SG&A is $424.60 million, with the most recent change of +$28.20 million (+7.11%) on June 30, 2025.
- Over the past year, VRTX quarterly SG&A has increased by +$52.40 million (+14.08%).
- VRTX quarterly SG&A is now at all-time high.
Performance
VRTX Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM SG&A:
$39.84B+$3.64B(+10.05%)Summary
- As of today, VRTX TTM SG&A is $39.84 billion, with the most recent change of +$3.64 billion (+10.05%) on June 30, 2025.
- Over the past year, VRTX TTM SG&A has increased by +$38.49 billion (+2855.91%).
- VRTX TTM SG&A is now at all-time high.
Performance
VRTX TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Selling, General & Administrative Expenses Formula
SG&A = Total Operating Expenses - Cost of Goods Sold - Research & Development
VRTX Selling, General & Administrative Expenses Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1Y1 Year | +28.8% | +14.1% | +2855.9% |
| 3Y3 Years | +74.3% | +97.2% | +4407.3% |
| 5Y5 Years | +122.4% | +121.4% | +5184.6% |
VRTX Selling, General & Administrative Expenses Highs & Lows
| PeriodPeriod | Annual vs HighAnnual vs High | Annual vs LowAnnual vs Low | Quarter. vs HighQuarter. vs High | Quarter. vs LowQuarter. vs Low | TTM vs HighTTM vs High | TTM vs LowTTM vs Low | |
|---|---|---|---|---|---|---|---|
| 3Y | 3-Year | at high | +74.3% | at high | +76.1% | at high | +125.8% |
| 5Y | 5-Year | at high | +122.4% | at high | +130.1% | at high | +1321.5% |
| All-Time | All-Time | at high | >+9999.0% | at high | >+9999.0% | at high | +285.7% |
VRTX Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2025 | - | $424.60M(+7.1%) | $1.57B(+3.5%) |
| Mar 2025 | - | $396.40M(+5.0%) | $1.52B(+3.7%) |
| Dec 2024 | $1.46B(+28.8%) | $377.60M(+1.6%) | $1.46B(+0.6%) |
| Sep 2024 | - | $371.80M(-0.1%) | $1.46B(+8.0%) |
| Jun 2024 | - | $372.20M(+8.6%) | $1.35B(+8.9%) |
| Mar 2024 | - | $342.70M(-7.2%) | $1.24B(+8.9%) |
| Dec 2023 | $1.14B(+20.3%) | $369.10M(+39.9%) | $1.14B(+9.8%) |
| Sep 2023 | - | $263.80M(+0.5%) | $1.03B(+1.7%) |
| Jun 2023 | - | $262.60M(+8.9%) | $1.02B(+4.9%) |
| Mar 2023 | - | $241.10M(-9.8%) | $970.60M(+2.7%) |
| Dec 2022 | $944.70M(+12.5%) | $267.40M(+8.3%) | $944.70M(+1.3%) |
| Sep 2022 | - | $246.80M(+14.6%) | $932.50M(+5.5%) |
| Jun 2022 | - | $215.30M(+0.0%) | $883.89M(+2.4%) |
| Mar 2022 | - | $215.20M(-15.7%) | $863.26M(+2.8%) |
| Dec 2021 | $840.10M(+9.0%) | $255.20M(+28.8%) | $840.13M(+5.4%) |
| Sep 2021 | - | $198.19M(+1.8%) | $796.78M(+1.7%) |
| Jun 2021 | - | $194.67M(+1.3%) | $783.14M(+0.4%) |
| Mar 2021 | - | $192.08M(-9.3%) | $780.27M(+1.3%) |
| Dec 2020 | $770.50M(+17.0%) | $211.84M(+14.8%) | $770.46M(+2.2%) |
| Sep 2020 | - | $184.55M(-3.8%) | $753.89M(+3.4%) |
| Jun 2020 | - | $191.80M(+5.2%) | $729.01M(+5.1%) |
| Mar 2020 | - | $182.26M(-6.7%) | $693.71M(+5.3%) |
| Dec 2019 | $658.50M(+18.1%) | $195.28M(+22.3%) | $658.50M(+6.8%) |
| Sep 2019 | - | $159.67M(+2.0%) | $616.43M(+3.8%) |
| Jun 2019 | - | $156.50M(+6.4%) | $594.05M(+3.3%) |
| Mar 2019 | - | $147.04M(-4.0%) | $574.85M(+3.1%) |
| Dec 2018 | $557.62M(+12.4%) | $153.21M(+11.6%) | $557.62M(+3.4%) |
| Sep 2018 | - | $137.29M(-0.0%) | $539.20M(+3.2%) |
| Jun 2018 | - | $137.30M(+5.8%) | $522.62M(+2.0%) |
| Mar 2018 | - | $129.81M(-3.7%) | $512.56M(+3.3%) |
| Dec 2017 | $496.08M(+14.6%) | $134.79M(+11.7%) | $496.08M(+5.3%) |
| Sep 2017 | - | $120.71M(-5.1%) | $471.19M(+3.2%) |
| Jun 2017 | - | $127.25M(+12.3%) | $456.54M(+3.5%) |
| Mar 2017 | - | $113.33M(+3.1%) | $440.94M(+1.9%) |
| Dec 2016 | $432.83M(+14.9%) | $109.91M(+3.6%) | $432.83M(+3.1%) |
| Sep 2016 | - | $106.06M(-5.0%) | $419.98M(+1.5%) |
| Jun 2016 | - | $111.65M(+6.1%) | $413.69M(+4.4%) |
| Mar 2016 | - | $105.21M(+8.4%) | $396.43M(+5.1%) |
| Dec 2015 | $376.57M(+23.3%) | $97.05M(-2.7%) | $377.08M(+5.2%) |
| Sep 2015 | - | $99.77M(+5.7%) | $358.55M(+7.3%) |
| Jun 2015 | - | $94.39M(+9.9%) | $334.00M(+5.3%) |
| Mar 2015 | - | $85.86M(+9.3%) | $317.06M(+3.8%) |
| Dec 2014 | $305.41M(-14.3%) | $78.53M(+4.4%) | $305.41M(+1.1%) |
| Sep 2014 | - | $75.22M(-2.9%) | $302.07M(-4.0%) |
| Jun 2014 | - | $77.45M(+4.4%) | $314.60M(-8.5%) |
| Mar 2014 | - | $74.21M(-1.3%) | $343.68M(-5.2%) |
| Dec 2013 | $356.19M(-17.7%) | $75.19M(-14.3%) | $362.34M(-8.9%) |
| Sep 2013 | - | $87.75M(-17.6%) | $397.61M(-2.4%) |
| Jun 2013 | - | $106.52M(+14.7%) | $407.54M(-2.6%) |
| Mar 2013 | - | $92.88M(-15.9%) | $418.53M(-4.2%) |
| Dec 2012 | $432.68M(+8.0%) | $110.45M(+13.1%) | $436.80M(-2.5%) |
| Sep 2012 | - | $97.68M(-16.9%) | $448.23M(-2.8%) |
| Jun 2012 | - | $117.51M(+5.7%) | $461.19M(+4.7%) |
| Mar 2012 | - | $111.15M(-8.8%) | $440.34M(+9.9%) |
| Dec 2011 | $400.72M(+113.4%) | $121.88M(+10.1%) | $400.72M(+17.4%) |
| Sep 2011 | - | $110.65M(+14.5%) | $341.32M(+22.1%) |
| Jun 2011 | - | $96.66M(+35.1%) | $279.52M(+24.9%) |
| Mar 2011 | - | $71.52M(+14.5%) | $223.77M(+19.2%) |
| Dec 2010 | $187.80M(+44.2%) | $62.48M(+27.9%) | $187.80M(+18.9%) |
| Sep 2010 | - | $48.85M(+19.4%) | $157.90M(+8.4%) |
| Jun 2010 | - | $40.91M(+15.1%) | $145.61M(+6.1%) |
| Mar 2010 | - | $35.55M(+9.1%) | $137.22M(+5.4%) |
| Dec 2009 | $130.19M(+28.5%) | $32.57M(-10.9%) | $130.19M(+2.3%) |
| Sep 2009 | - | $36.57M(+12.4%) | $127.27M(+8.0%) |
| Jun 2009 | - | $32.53M(+14.0%) | $117.89M(+3.2%) |
| Mar 2009 | - | $28.52M(-3.8%) | $114.25M(+6.4%) |
| Dec 2008 | $101.29M | $29.66M(+9.1%) | $107.36M(+6.1%) |
| Sep 2008 | - | $27.19M(-5.9%) | $101.15M(+6.1%) |
| Jun 2008 | - | $28.89M(+33.6%) | $95.38M(+6.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2008 | - | $21.62M(-7.8%) | $89.81M(+6.0%) |
| Dec 2007 | $84.73M(+46.4%) | $23.45M(+9.5%) | $84.73M(+9.9%) |
| Sep 2007 | - | $21.42M(-8.2%) | $77.11M(+9.4%) |
| Jun 2007 | - | $23.32M(+41.0%) | $70.47M(+14.6%) |
| Mar 2007 | - | $16.54M(+4.4%) | $61.52M(+6.3%) |
| Dec 2006 | $57.86M(+31.5%) | $15.84M(+7.2%) | $57.86M(+5.5%) |
| Sep 2006 | - | $14.77M(+2.8%) | $54.83M(+7.9%) |
| Jun 2006 | - | $14.37M(+11.6%) | $50.80M(+7.5%) |
| Mar 2006 | - | $12.88M(+0.5%) | $47.24M(+7.4%) |
| Dec 2005 | $43.99M(+4.4%) | $12.81M(+19.3%) | $43.99M(+2.7%) |
| Sep 2005 | - | $10.74M(-0.7%) | $42.84M(+0.3%) |
| Jun 2005 | - | $10.81M(+12.3%) | $42.70M(+22.8%) |
| Mar 2005 | - | $9.63M(-17.4%) | $34.76M(-0.3%) |
| Dec 2004 | $42.14M(+7.8%) | $11.66M(+10.0%) | $34.85M(+3.5%) |
| Sep 2004 | - | $10.60M(+268.6%) | $33.67M(+1.9%) |
| Jun 2004 | - | $2.88M(-70.4%) | $33.05M(-18.1%) |
| Mar 2004 | - | $9.72M(-7.2%) | $40.37M(-4.1%) |
| Dec 2003 | $39.08M(-4.8%) | $10.47M(+5.0%) | $42.10M(-3.5%) |
| Sep 2003 | - | $9.97M(-2.2%) | $43.65M(-6.3%) |
| Jun 2003 | - | $10.20M(-10.9%) | $46.60M(-6.3%) |
| Mar 2003 | - | $11.45M(-4.7%) | $49.75M(+0.7%) |
| Dec 2002 | $41.06M(+28.9%) | $12.02M(-7.0%) | $49.39M(+32.2%) |
| Sep 2002 | - | $12.93M(-3.1%) | $37.37M(+2.6%) |
| Jun 2002 | - | $13.35M(+20.3%) | $36.43M(+9.5%) |
| Mar 2002 | - | $11.10M(>+9900.0%) | $33.26M(+12.1%) |
| Dec 2001 | $31.86M(-23.0%) | $0.00(-100.0%) | $29.66M(0.0%) |
| Sep 2001 | - | $11.99M(+17.8%) | $29.66M(+67.9%) |
| Jun 2001 | - | $10.18M(+35.8%) | $17.67M(+135.8%) |
| Mar 2001 | - | $7.50M(>+9900.0%) | $7.50M(>+9900.0%) |
| Dec 2000 | $41.35M(+58.4%) | $0.00(0.0%) | $0.00(0.0%) |
| Sep 2000 | - | $0.00(0.0%) | $0.00(0.0%) |
| Jun 2000 | - | $0.00(0.0%) | $0.00(0.0%) |
| Mar 2000 | - | $0.00(0.0%) | $0.00(0.0%) |
| Dec 1999 | $26.10M(+44.2%) | $0.00(0.0%) | $0.00(0.0%) |
| Sep 1999 | - | $0.00(0.0%) | $0.00(0.0%) |
| Jun 1999 | - | $0.00(0.0%) | $0.00(0.0%) |
| Mar 1999 | - | $0.00(0.0%) | $0.00(0.0%) |
| Dec 1998 | $18.10M(+58.8%) | $0.00(0.0%) | $0.00(-100.0%) |
| Sep 1998 | - | $0.00(0.0%) | $3.70M(-43.1%) |
| Jun 1998 | - | $0.00(0.0%) | $6.50M(-28.6%) |
| Mar 1998 | - | $0.00(-100.0%) | $9.10M(-19.5%) |
| Dec 1997 | $11.40M(-50.2%) | $3.70M(+32.1%) | $11.30M(-54.8%) |
| Sep 1997 | - | $2.80M(+7.7%) | $25.00M(+4.2%) |
| Jun 1997 | - | $2.60M(+18.2%) | $24.00M(+3.0%) |
| Mar 1997 | - | $2.20M(-87.4%) | $23.30M(+1.7%) |
| Dec 1996 | $22.90M(+222.5%) | $17.40M(+866.7%) | $22.90M(+201.3%) |
| Sep 1996 | - | $1.80M(-5.3%) | $7.60M(+1.3%) |
| Jun 1996 | - | $1.90M(+5.6%) | $7.50M(+2.7%) |
| Mar 1996 | - | $1.80M(-14.3%) | $7.30M(+2.8%) |
| Dec 1995 | $7.10M(-82.4%) | $2.10M(+23.5%) | $7.10M(-55.9%) |
| Sep 1995 | - | $1.70M(0.0%) | $16.10M(-34.8%) |
| Jun 1995 | - | $1.70M(+6.3%) | $24.70M(-25.6%) |
| Mar 1995 | - | $1.60M(-85.6%) | $33.20M(-17.8%) |
| Dec 1994 | $40.30M(+50.9%) | $11.10M(+7.8%) | $40.40M(+4.4%) |
| Sep 1994 | - | $10.30M(+1.0%) | $38.70M(+8.4%) |
| Jun 1994 | - | $10.20M(+15.9%) | $35.70M(+14.8%) |
| Mar 1994 | - | $8.80M(-6.4%) | $31.10M(+16.5%) |
| Dec 1993 | $26.70M(+93.5%) | $9.40M(+28.8%) | $26.70M(+25.9%) |
| Sep 1993 | - | $7.30M(+30.4%) | $21.20M(+21.1%) |
| Jun 1993 | - | $5.60M(+27.3%) | $17.50M(+40.0%) |
| Mar 1993 | - | $4.40M(+12.8%) | $12.50M(+12.6%) |
| Dec 1992 | $13.80M(+56.8%) | $3.90M(+8.3%) | $11.10M(+14.4%) |
| Sep 1992 | - | $3.60M(+500.0%) | $9.70M(+16.9%) |
| Jun 1992 | - | $600.00K(-80.0%) | $8.30M(-15.3%) |
| Mar 1992 | - | $3.00M(+20.0%) | $9.80M(+44.1%) |
| Dec 1991 | $8.80M(+37.5%) | $2.50M(+13.6%) | $6.80M(+58.1%) |
| Sep 1991 | - | $2.20M(+4.8%) | $4.30M(+104.8%) |
| Jun 1991 | - | $2.10M | $2.10M |
| Dec 1990 | $6.40M | - | - |
FAQ
- What is Vertex Pharmaceuticals Incorporated annual SG&A?
- What is the all-time high annual SG&A for Vertex Pharmaceuticals Incorporated?
- What is Vertex Pharmaceuticals Incorporated annual SG&A year-on-year change?
- What is Vertex Pharmaceuticals Incorporated quarterly SG&A?
- What is the all-time high quarterly SG&A for Vertex Pharmaceuticals Incorporated?
- What is Vertex Pharmaceuticals Incorporated quarterly SG&A year-on-year change?
- What is Vertex Pharmaceuticals Incorporated TTM SG&A?
- What is the all-time high TTM SG&A for Vertex Pharmaceuticals Incorporated?
- What is Vertex Pharmaceuticals Incorporated TTM SG&A year-on-year change?
What is Vertex Pharmaceuticals Incorporated annual SG&A?
The current annual SG&A of VRTX is $1.46B
What is the all-time high annual SG&A for Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated all-time high annual SG&A is $1.46B
What is Vertex Pharmaceuticals Incorporated annual SG&A year-on-year change?
Over the past year, VRTX annual SG&A has changed by +$327.70M (+28.83%)
What is Vertex Pharmaceuticals Incorporated quarterly SG&A?
The current quarterly SG&A of VRTX is $424.60M
What is the all-time high quarterly SG&A for Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated all-time high quarterly SG&A is $424.60M
What is Vertex Pharmaceuticals Incorporated quarterly SG&A year-on-year change?
Over the past year, VRTX quarterly SG&A has changed by +$52.40M (+14.08%)
What is Vertex Pharmaceuticals Incorporated TTM SG&A?
The current TTM SG&A of VRTX is $39.84B
What is the all-time high TTM SG&A for Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated all-time high TTM SG&A is $39.84B
What is Vertex Pharmaceuticals Incorporated TTM SG&A year-on-year change?
Over the past year, VRTX TTM SG&A has changed by +$38.49B (+2855.91%)